Yuan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuan Zhao has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Ching-Shih Chen
College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
2 shared publicationsJinru Wu
The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine Shenzhen 518033 China
2 shared publicationsJohn C. Byrd
Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
2 shared publicationsL. James Lee
Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices (CANPBD), The Ohio State University, Columbus, OH 43210, USA
2 shared publicationsLin Zheng
The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine Shenzhen 518033 China
2 shared publications- Mitch A. Phelps
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, United States
2 shared publications
Latest Publications
- 11 October 2024
- Published by Wiley in Biomedical Chromatography
- Vol. 38 (12) , e6023
Huangqi‐Guizhi‐Wuwutang protects against oligospermia in mice by promoting the proliferation of spermatogenic stem cells: A comprehensive study using HPLC‐Q‐TOF/MS and experimental pharmacology
The classical traditional Chinese medicine formula Huangqi‐Guizhi‐Wuwutang (HGW) has been shown to enhance sperm production. However, the bioactive components and comprehensive mechanisms underlying the therapeutic effects remain unclear. The present study investigates the potential active ingredients and underlying mechanisms of HGW against spermatogenesis dysfunction. The chemical components of HGW were analyzed by mass spectrometry. And then the “components‐targets‐pathway‐disease” network was constructed using network pharmacology research methods, which aimed to identify the key active components and potential targets of HGW in treating oligospermia. Experimental validation was finally conducted in animal model. The male‐specific pathogen‐free Kunming mice were divided into five groups: Sham group, Model group, and HGW groups (8, 16, and 32 g/kg of HGW by gavage for 35 days). Chemical profile and network pharmacology results revealed that potential bioactive compounds were dihydrocinnacasside, isomucronulatol, and 6‐gingerol, and the mechanism of which was enriched in regulating spermatogenic stem cells (SSCs), endocrine function, and apoptosis. The administration of HGW significantly improved oligospermia in mice. HGW significantly upregulated the expression of marker proteins in SSCs and the potential targets within the testis simultaneously. Our data indicates that HGW enhances the proliferation of SSCs, and HGW can be a promising therapeutic candidate for oligospermia.
- 11 October 2024
- Published by Wiley in Biomedical Chromatography
- Vol. 38 (12) , e6023
Huangqi‐Guizhi‐Wuwutang protects against oligospermia in mice by promoting the proliferation of spermatogenic stem cells: A comprehensive study using HPLC‐Q‐TOF/MS and experimental pharmacology
The classical traditional Chinese medicine formula Huangqi‐Guizhi‐Wuwutang (HGW) has been shown to enhance sperm production. However, the bioactive components and comprehensive mechanisms underlying the therapeutic effects remain unclear. The present study investigates the potential active ingredients and underlying mechanisms of HGW against spermatogenesis dysfunction. The chemical components of HGW were analyzed by mass spectrometry. And then the “components‐targets‐pathway‐disease” network was constructed using network pharmacology research methods, which aimed to identify the key active components and potential targets of HGW in treating oligospermia. Experimental validation was finally conducted in animal model. The male‐specific pathogen‐free Kunming mice were divided into five groups: Sham group, Model group, and HGW groups (8, 16, and 32 g/kg of HGW by gavage for 35 days). Chemical profile and network pharmacology results revealed that potential bioactive compounds were dihydrocinnacasside, isomucronulatol, and 6‐gingerol, and the mechanism of which was enriched in regulating spermatogenic stem cells (SSCs), endocrine function, and apoptosis. The administration of HGW significantly improved oligospermia in mice. HGW significantly upregulated the expression of marker proteins in SSCs and the potential targets within the testis simultaneously. Our data indicates that HGW enhances the proliferation of SSCs, and HGW can be a promising therapeutic candidate for oligospermia.
- 9 October 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319, 117260
Protective effect of Huangqi-Guizhi-Wuwutang against cyclophosphamide-induced spermatogenesis dysfunction in mice by promoting steroid hormone biosynthesis
- 9 October 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 319, 117260
Protective effect of Huangqi-Guizhi-Wuwutang against cyclophosphamide-induced spermatogenesis dysfunction in mice by promoting steroid hormone biosynthesis
- Open Access
- 22 May 2014
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 98, 160-165
Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography–tandem mass spectrometry
- 22 May 2014
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 98, 160-165
Open AccessQuantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography–tandem mass spectrometry
- Open Access
- 1 February 2014
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 10 (2) , 393-400
A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery
- 1 February 2014
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 10 (2) , 393-400
Open AccessA novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery